BioXcel Therapeutics (BTAI) Cash from Financing Activities (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Cash from Financing Activities of $232000.0 for Q1 2026, down 98.24% year-over-year from $13.2 million in Q1 2025, and down 95.89% quarter-over-quarter from $5.6 million in Q4 2025.
BioXcel Therapeutics (BTAI) Cash from Financing Activities (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $232000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 98.24% year-over-year to $232000.0; the TTM figure through Mar 2026 stood at $43.5 million (up 87.42% YoY), while the FY2025 annual figure was $56.5 million, up 54.17% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $232000.0, down from $5.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $37.5 million in Q3 2025, with the low at $50000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is $4.8 million (2024), against an average of $10.7 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities surged 42221.13% in 2022, then tumbled 98.24% in 2026.
- BioXcel Therapeutics' Cash from Financing Activities stood at $50000.0 in 2022, then jumped by 4146.0% to $2.1 million in 2023, then jumped by 101.41% to $4.3 million in 2024, then surged by 32.06% to $5.6 million in 2025, then sank by 95.89% to $232000.0 in 2026.
- Business Quant data shows BTAI's Cash from Financing Activities at $232000.0 in Q1 2026, $5.6 million in Q4 2025, and $37.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.46 Mn | 24.46 Mn | 160,000.00 | 2.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.72 Mn |
| Jun 30, 2026 | 2.72 Mn |
| Mar 31, 2026 | 232,000.00 |
| Mar 31, 2026 | 232,000.00 |
| Dec 31, 2025 | 5.65 Mn |
| Dec 31, 2025 | 5.65 Mn |
| Sep 30, 2025 | 37.53 Mn |
| Sep 30, 2025 | 37.53 Mn |
| Jun 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 137,000.00 |
| Mar 31, 2025 | 13.20 Mn |
| Mar 31, 2025 | 13.20 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Sep 30, 2024 | 454,000.00 |
| Sep 30, 2024 | 454,000.00 |
| Jun 30, 2024 | 5.30 Mn |
| Jun 30, 2024 | 5.30 Mn |
| Mar 31, 2024 | 26.63 Mn |
| Mar 31, 2024 | 26.63 Mn |